Ipsos Healthcare Debuts NASH Therapy Monitor in Japan

Ipsos Healthcare has extended its Global Nonalcoholic Steatohepatitis (NASH) Therapy Monitor to Japan.

NASH, which is part of Ipsos' Virology & Liver Diseases Real World Evidence portfolio, was launched in the EU5 and US last year. The new Japanese syndicated study will combine actual patient data with physician perceptions, while globally comparable data will allow for cross-market comparisons. Ultimately, subscribers will be able to evaluate and size NASH patient segments, understand patient journeys, identify referral patterns and stakeholder involvement, and pinpoint doctors' expectations on required clinical endpoints for NASH trials.

Dr Sabina Heinz (pictured), Ipsos' Director of Real World Evidence in Global Diseases, comments: 'Although Japan has the lowest rate of obesity in the industrialised world, it is on the rise. Furthermore, the prevalence of fatty liver in Japan has increased over the past ten years. With both factors contributing to Nonalcoholic Steatohepatitis, we expect to see a growing incidence of the disease in Japan. The Japanese NASH Therapy Monitor will enable our clients to better understand the dynamics of this emerging disease and identify any unmet needs specifically in this market for Japanese patients'.

Web site: www.ipsos.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.